# Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

> **NCT07221370** · PHASE2,PHASE3 · RECRUITING · sponsor: **Riverside University Health System Medical Center** · enrollment: 176 (estimated)

## Conditions studied

- Clostridium Difficile Infection
- Vancomycin Resistant Enterococci Infection

## Interventions

- **DRUG:** Vancomycin 125mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07221370
- **Lead sponsor:** Riverside University Health System Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221370, "Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07221370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*